Published in Clin Dev Immunol on November 03, 2011
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Radiation, inflammation, and immune responses in cancer. Front Oncol (2012) 1.25
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ (2013) 1.12
Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11
Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue. Br J Cancer (2013) 1.06
Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04
The Role of TLR4 in Chemotherapy-Driven Metastasis. Cancer Res (2015) 0.95
Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther (2013) 0.94
HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer (2015) 0.92
A protective Hsp70-TLR4 pathway in lethal oxidant lung injury. J Immunol (2013) 0.91
Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders. Sci Signal (2015) 0.87
Topographical changes in extracellular matrix: Activation of TLR4 signaling and solid tumor progression. Trends Cancer Res (2013) 0.85
Evidence of a paradoxical relationship between endotoxin and lung cancer after accounting for left truncation in a study of Chinese female textile workers. Occup Environ Med (2013) 0.84
Rationally Designed Macrocyclic Peptides as Synergistic Agonists of LPS-Induced Inflammatory Response. Tetrahedron (2014) 0.81
Toll-like receptor-4 modulation for cancer immunotherapy. Front Immunol (2014) 0.81
Reevaluating the concept of treating experimental tumors with a mixed bacterial vaccine: Coley's Toxin. Clin Dev Immunol (2012) 0.80
TLR4-MyD88-TRAF6-TAK1 Complex-Mediated NF-κB Activation Contribute to the Anti-Inflammatory Effect of V8 in LPS-Induced Human Cervical Cancer SiHa Cells. Inflammation (2016) 0.80
The association of toll-like receptor 4 polymorphism with hepatitis C virus infection in Saudi Arabian patients. Biomed Res Int (2014) 0.78
Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects. Int J Cancer (2015) 0.78
European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biol (2017) 0.77
Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments. Cancer Gene Ther (2014) 0.77
Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4/NF-κB pathway. Sci Rep (2016) 0.77
Proton irradiation augments the suppression of tumor progression observed with advanced age. Radiat Res (2014) 0.77
Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine. J Pharm Sci (2016) 0.76
Toll-like receptor 4 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review. Arch Med Sci (2015) 0.76
NOD-Like Receptor Protein 3 Inflammasome Priming and Activation in Barrett's Epithelial Cells. Cell Mol Gastroenterol Hepatol (2016) 0.75
Identification of key target genes and pathways in laryngeal carcinoma. Oncol Lett (2016) 0.75
Cellular uptake of exogenous calcineurin B is dependent on TLR4/MD2/CD14 complexes, and CnB is an endogenous ligand of TLR4. Sci Rep (2016) 0.75
Structure of a TLR4-interacting SPA4 peptide. RSC Adv (2015) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
Cancer-related inflammation. Nature (2008) 34.21
CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (1990) 17.86
TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest (2006) 17.49
The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell (1996) 17.42
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Taking dendritic cells into medicine. Nature (2007) 11.82
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
TLR signaling. Cell Death Differ (2006) 9.24
MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med (1999) 9.23
The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature (2009) 8.99
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med (2001) 8.60
Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med (2005) 8.49
Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem (2003) 8.34
Regulation of phagosome maturation by signals from toll-like receptors. Science (2004) 6.79
Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol (2000) 6.57
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem (2002) 6.16
Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med (2002) 5.70
HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol (2010) 5.65
Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature (2006) 5.54
Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med (2007) 5.47
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol (2005) 5.04
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis (2009) 5.01
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science (2007) 4.90
The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem (2001) 4.74
Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest (2006) 4.72
HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (2006) 4.53
Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science (2002) 4.45
The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell (1988) 4.36
HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem (2002) 4.03
The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest (2005) 3.99
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med (2009) 3.87
Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol (2001) 3.76
Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A (2006) 3.70
Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut (1988) 3.66
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol (2002) 3.32
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res (2006) 3.21
Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol (2002) 3.20
Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science (2004) 3.08
The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol (2009) 3.01
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol (2010) 2.85
Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem (2007) 2.82
L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol (2003) 2.81
Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem (2004) 2.81
Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem (2002) 2.66
Developmental control of endocytosis in dendritic cells by Cdc42. Cell (2000) 2.64
Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity (2006) 2.51
Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol (2005) 2.41
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol (2009) 2.36
Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol (2006) 2.30
Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem (2009) 2.12
IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol (2004) 2.12
Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun (2000) 2.10
Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol (2002) 2.04
The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol Genomics (2004) 2.03
Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol (2002) 1.92
MD-2 binds to bacterial lipopolysaccharide. J Biol Chem (2001) 1.91
High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol (2008) 1.88
CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med (2010) 1.64
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother (2010) 1.60
Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol (2010) 1.59
High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer (2010) 1.56
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53
Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer (2010) 1.53
TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene (2009) 1.52
Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol (2008) 1.50
Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol (2005) 1.49
Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem (2003) 1.42
Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res (2010) 1.38
Essential roles of hydrophobic residues in both MD-2 and toll-like receptor 4 in activation by endotoxin. J Biol Chem (2009) 1.38
The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate (2008) 1.38
TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J (2010) 1.37
The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer (1999) 1.37
Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infect Immun (2003) 1.33
Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol (2010) 1.27
Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol (2010) 1.27
Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol (2008) 1.25
Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. Microbes Infect (2006) 1.25
Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther (2008) 1.23
Hyaluronan fragments generated by sperm-secreted hyaluronidase stimulate cytokine/chemokine production via the TLR2 and TLR4 pathway in cumulus cells of ovulated COCs, which may enhance fertilization. Development (2008) 1.22
Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother (2009) 1.21
Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol (2009) 1.19
Ceramide as a TLR4 agonist; a putative signalling intermediate between sphingolipid receptors for microbial ligands and TLR4. Cell Microbiol (2007) 1.19
TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol (2008) 1.16
The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol (2007) 1.16
Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett (2006) 1.15
Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation. Immunity (2010) 1.15
Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother (2010) 1.14
Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of beta-defensin 2 via TLR2 and TLR4. J Immunol (2008) 1.14
The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med (2010) 1.14
Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol (2011) 1.83
The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes. PLoS One (2008) 1.70
Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition. J Biol Chem (2004) 1.48
Essential roles of hydrophobic residues in both MD-2 and toll-like receptor 4 in activation by endotoxin. J Biol Chem (2009) 1.38
Design of a single-chain polypeptide tetrahedron assembled from coiled-coil segments. Nat Chem Biol (2013) 1.32
Globular domain of the prion protein needs to be unlocked by domain swapping to support prion protein conversion. J Biol Chem (2011) 1.29
Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricin-derived peptide. Biochem J (2005) 1.28
DNA-guided assembly of biosynthetic pathways promotes improved catalytic efficiency. Nucleic Acids Res (2011) 1.28
MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol (2007) 1.26
A second binding site for double-stranded RNA in TLR3 and consequences for interferon activation. Nat Struct Mol Biol (2008) 1.24
Enhancement of antibacterial and lipopolysaccharide binding activities of a human lactoferrin peptide fragment by the addition of acyl chain. J Antimicrob Chemother (2003) 1.24
The lipopolysaccharide core of Brucella abortus acts as a shield against innate immunity recognition. PLoS Pathog (2012) 1.17
Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt-Jacob's disease-affected and normal brain tissue. J Biol Chem (2003) 1.09
Taxanes inhibit human TLR4 signaling by binding to MD-2. FEBS Lett (2008) 1.09
Characterization of quercetin binding site on DNA gyrase. Biochem Biophys Res Commun (2003) 1.07
Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. J Med Chem (2007) 1.05
Similarities and specificities of fungal keratinolytic proteases: comparison of keratinases of Paecilomyces marquandii and Doratomyces microsporus to some known proteases. Appl Environ Microbiol (2005) 1.04
Curcumin binds to the alpha-helical intermediate and to the amyloid form of prion protein - a new mechanism for the inhibition of PrP(Sc) accumulation. J Neurochem (2007) 1.01
Nanoparticles isolated from blood: a reflection of vesiculability of blood cells during the isolation process. Int J Nanomedicine (2011) 1.01
Structural origin of endotoxin neutralization and antimicrobial activity of a lactoferrin-based peptide. J Biol Chem (2005) 1.01
The differential interaction of Brucella and ochrobactrum with innate immunity reveals traits related to the evolution of stealthy pathogens. PLoS One (2009) 1.01
The ectodomain of the Toll-like receptor 4 prevents constitutive receptor activation. J Biol Chem (2011) 0.99
The acyl group as the central element of the structural organization of antimicrobial lipopeptide. J Am Chem Soc (2007) 0.98
Identification of LPS-binding peptide fragment of MD-2, a toll-receptor accessory protein. Biochem Biophys Res Commun (2002) 0.96
Novel roles of lysines 122, 125, and 58 in functional differences between human and murine MD-2. J Immunol (2009) 0.96
Structural similarity between the hydrophobic fluorescent probe and lipid A as a ligand of MD-2. FASEB J (2006) 0.96
Expression, purification and structural studies of a short antimicrobial peptide. Biochim Biophys Acta (2008) 0.95
Alexidine and chlorhexidine bind to lipopolysaccharide and lipoteichoic acid and prevent cell activation by antibiotics. J Antimicrob Chemother (2008) 0.94
Structural features governing the activity of lactoferricin-derived peptides that act in synergy with antibiotics against Pseudomonas aeruginosa in vitro and in vivo. Antimicrob Agents Chemother (2010) 0.94
Functional activity of MD-2 polymorphic variant is significantly different in soluble and TLR4-bound forms: decreased endotoxin binding by G56R MD-2 and its rescue by TLR4 ectodomain. J Immunol (2008) 0.94
Biophysical characterization of the interaction of Limulus polyphemus endotoxin neutralizing protein with lipopolysaccharide. Eur J Biochem (2004) 0.93
Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation. J Biol Chem (2009) 0.93
The role of UNC93B1 protein in surface localization of TLR3 receptor and in cell priming to nucleic acid agonists. J Biol Chem (2012) 0.92
Comparative analysis of selected methods for the assessment of antimicrobial and membrane-permeabilizing activity: a case study for lactoferricin derived peptides. BMC Microbiol (2008) 0.92
Studies on lactoferricin-derived Escherichia coli membrane-active peptides reveal differences in the mechanism of N-acylated versus nonacylated peptides. J Biol Chem (2011) 0.92
De novo design of orthogonal peptide pairs forming parallel coiled-coil heterodimers. J Pept Sci (2010) 0.91
Influence of N-acylation of a peptide derived from human lactoferricin on membrane selectivity. Biochim Biophys Acta (2006) 0.91
Chemistry of lipid A: at the heart of innate immunity. Chemistry (2014) 0.91
Tetracysteine-tagged prion protein allows discrimination between the native and converted forms. FEBS J (2010) 0.88
Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Curr Opin Mol Ther (2009) 0.87
NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1β and neuronal toxicity. Cell Mol Life Sci (2012) 0.86
Interaction of the HIV-1 gp120 viral protein V3 loop with bacterial lipopolysaccharide: a pattern recognition inhibition. J Biol Chem (2011) 0.86
Postulates for validating TLR4 agonists. Eur J Immunol (2015) 0.85
Self-assembled bionanostructures: proteins following the lead of DNA nanostructures. J Nanobiotechnology (2014) 0.85
Chimeric flagellin as the self-adjuvanting antigen for the activation of immune response against Helicobacter pylori. Vaccine (2012) 0.85
Semiautomatic sequence-specific assignment of proteins based on the tertiary structure--the program st2nmr. J Comput Chem (2002) 0.85
Determination of the physiological 2:2 TLR5:flagellin activation stoichiometry revealed by the activity of a fusion receptor. Biochem Biophys Res Commun (2013) 0.84
Toll/interleukin-1 receptor domain dimers as the platform for activation and enhanced inhibition of Toll-like receptor signaling. J Biol Chem (2012) 0.84
MD-2 and Der p 2 - a tale of two cousins or distant relatives? J Endotoxin Res (2005) 0.84
Noninvasive high-throughput single-cell analysis of HIV protease activity using ratiometric flow cytometry. Sensors (Basel) (2013) 0.83
In silico discovery and biophysical evaluation of novel 5-(2-hydroxybenzylidene) rhodanine inhibitors of DNA gyrase B. Bioorg Med Chem (2012) 0.83
Tetraacylated lipid A and paclitaxel-selective activation of TLR4/MD-2 conferred through hydrophobic interactions. J Immunol (2014) 0.82
Suppression of TLR signaling by targeting TIR domain-containing proteins. Curr Protein Pept Sci (2012) 0.81
Production of recombinant antimicrobial peptides in bacteria. Methods Mol Biol (2010) 0.81
Conformationally constrained lipid A mimetics for exploration of structural basis of TLR4/MD-2 activation by lipopolysaccharide. ACS Chem Biol (2013) 0.81
The role of intermediary domain of MyD88 in cell activation and therapeutic inhibition of TLRs. J Immunol (2011) 0.81
Different functional role of domain boundaries of Toll-like receptor 4. Biochem Biophys Res Commun (2009) 0.81
New designed protein assemblies. Curr Opin Chem Biol (2013) 0.81
Functional self-assembling polypeptide bionanomaterials. Biochem Soc Trans (2012) 0.80
Disulfide mapping reveals the domain swapping as the crucial process of the structural conversion of prion protein. Prion (2011) 0.80
MARCKS as a negative regulator of lipopolysaccharide signaling. J Immunol (2012) 0.80
Comparison of backbone dynamics of monomeric and domain-swapped stefin A. Proteins (2004) 0.80
Mixed-valence Cu(II)/Cu(I) complex of quinolone ciprofloxacin isolated by a hydrothermal reaction in the presence of L-histidine: comparison of biological activities of various copper-ciprofloxacin compounds. J Inorg Biochem (2005) 0.79
In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. Bioorg Med Chem Lett (2005) 0.79
Prevention of microvesiculation by adhesion of buds to the mother cell membrane--a possible anticoagulant effect of healthy donor plasma. Autoimmun Rev (2007) 0.79
Expression of soluble versatile peroxidase of Bjerkandera adusta in Escherichia coli. Bioresour Technol (2008) 0.78
Introduction of glutamines into the B2-H2 loop promotes prion protein conversion. Biochem Biophys Res Commun (2011) 0.78
Protein inhibitors form complexes with procathepsin L and augment cleavage of the propeptide. Arch Biochem Biophys (2003) 0.77
Delivery system for the enhanced efficiency of immunostimulatory nucleic acids. Innate Immun (2012) 0.77
Interactions of archaeal chromatin proteins Alba1 and Alba2 with nucleic acids. PLoS One (2013) 0.77
Development of αGlcN(1↔1)αMan-based lipid A mimetics as a novel class of potent Toll-like receptor 4 agonists. J Med Chem (2014) 0.77
TOPOFOLD, the designed modular biomolecular folds: polypeptide-based molecular origami nanostructures following the footsteps of DNA. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.77
Combination of antimicrobial and endotoxin-neutralizing activities of novel oleoylamines. Antimicrob Agents Chemother (2005) 0.76
Modulation of CD14 and TLR4·MD-2 activities by a synthetic lipid A mimetic. Chembiochem (2013) 0.76
Effect of hydrophobic mutations in the H2-H3 subdomain of prion protein on stability and conversion in vitro and in vivo. PLoS One (2011) 0.76
Trehalose- and glucose-derived glycoamphiphiles: small-molecule and nanoparticle Toll-like receptor 4 (TLR4) modulators. J Med Chem (2014) 0.76
Preparation of chimeric genes without subcloning. Biotechniques (2004) 0.75
A DNA origami of slovenia in nano dimensions. Acta Chim Slov (2011) 0.75
Modulation of coiled-coil dimer stability through surface residues while preserving pairing specificity. J Am Chem Soc (2017) 0.75